Reading SCYX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track SCYX free→Reading SCYX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track SCYX free→NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-06-15
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is neutral. Earnings quality cannot be assessed since the company was unprofitable over the past year. Management's recent track record has been fairly steady. Risk is moderate, and the sector backdrop is a headwind. Compared with sector peers, SCYX trades below typical levels. Peer multiples imply a price about 75% above where it trades (it looks cheap on this basis); the read is cheap, value-trap risk. This pattern occurs because recent financials are weak or earnings quality is fragile. The read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 3 valuation methods, at three horizons. Current price $4.09. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $4.09 SCYX trades at 3× p/e, below its 13× p/e peer median. Our $16 fair value sits above the price; medium confidence. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price implies about 75% below a flat-multiple fair value, below our forecast of about 100%. This describes what's priced in, not a forecast of the move.
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 50% of the time over the next year (vs 57% for the rest of the cohort, n=3115).
Over the trailing year it converted 0.24x of net income into operating cash flow.
Not enough signal yet.
6 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated neutral grew net income 58% of the time over the next year (vs 50% for the rest of the cohort, n=842).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $-0.83 → $-0.51 (+38.7% / 30d). 1 raised, 0 cut, 3 covering analysts.
0 upgrades, 0 downgrades / 30d. 100% of analysts rate Buy.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
Not enough price history for this read.
How much price usually moves either way.
Not enough price history for this read.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $1,980.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-15
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
No named catalysts to watch right now. Check back after the next earnings report.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for SCYX yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On April 16, 2026, Steven C. Gilman, a member of the Board of Directors (the “Board”) of SCYNEXIS, Inc. (the “Company”), notified the Company of his intent to retire as a member of the Board and therefore not stand for reelection at the Company’s 2026 annual meeting of stockholders (the “2026 Annual Meeting”). Accordingly, Dr. Gilman’s term as a dir…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
Looks cheaper than most peers in the same business.
Self-history needs ~20 months of data.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Pharmaceuticals.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
SCYX SCYNEXIS Inc | Below typical Show detailsSector percentile: 5 of 100 | inexpensive | moderate |
LLY Lilly (Eli) | Above typical Show detailsSector percentile: 88 of 100 | expensive | moderate |
JNJ Johnson & Johnson | Above typical Show detailsSector percentile: 74 of 100 | expensive | low |
MRK Merck & Co. | Typical Show detailsSector percentile: 67 of 100 | expensive | moderate |
PFE Pfizer | Typical Show detailsSector percentile: 61 of 100 | fair | low |
Not investment advice. As of 2026-06-15.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-15.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
SCYNEXIS aims to integrate Poxel's AMP kinase activator research and development program assets.
Newly stated in 2026-Q1. SCYNEXIS completed the acquisition of Poxel's AMP kinase activator assets, marking a strategic move to enhance its research and development capabilities. This acquisition aligns with the company's growth strategy, but financial impacts are not yet reflected in the current financials.
“SCYNEXIS completed the acquisition of Poxel's AMP kinase activator assets.”
SCYNEXIS plans to use proceeds from a private placement to fund operations into mid-2029.
Newly stated in 2026-Q1. SCYNEXIS has secured funding through a private placement, which is expected to support operations into mid-2029. This capital allocation strategy is crucial given the company's current financials, with a net income of -$21.3M in 2026-Q1 and no revenue reported.
“The company estimates that proceeds from the private placement will fund operations into mid-2029.”
SCYNEXIS targets up to $146M in sales milestones for BREXAFEMME.
Newly stated in 2026-Q1. SCYNEXIS aims to achieve up to $146M in BREXAFEMME sales milestones. However, the current financials show no revenue in 2026-Q1, indicating that progress towards this target has not yet materialized in reported results.
“Potential to receive up to $146M in BREXAFEMME sales milestones.”
Completion of Acquisition or Disposition of Assets. The information contained above in
Entry into a Material Definitive Agreement. Asset Purchase Agreement On March 30, 2026, SCYNEXIS, Inc. (the “Company”) and Poxel SA, a French corporation (“Poxel”), entered into an asset purchase agreement (the “Asset Purchase Agreement”) pursuant to which the Company (i) acquired all of Poxel’s right, title and interest in Poxel’s direct AMP kinase activator research and development program assets, including all patents, know-how, regulatory filings, inventory, records, assumed contracts and…
Entry into a Material Definitive Agreement. Private Placement On March 30, 2026, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain new and existing institutional and accredited investors (the “Investors”) pursuant to which the Company, in a private placement (the “Private Placement”), agreed to issue and sell to the Investors an aggregate of (i) 34,750,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Commo…
The Shares and Warrants have not been registered under the Securities Act, in reliance on the exemption from registration afforded by Section 4(a)(2) of the Securities Act. Each of the Investors has provided representations appropriate for a private placement of securities. The sale of the Shares and the Warrants did not involve a public offering and was made without general solicitation or general advertising. Neither this Current Report on Form 8-K nor any exhibit attached hereto is an offe…